How Vertex’s Revenue and Earnings Surprised in 2Q16
Vertex Pharmaceuticals (VRTX) reported its 2Q16 earnings on July 27, 2016. VRTX surpassed Wall Street analysts’ projections and reported revenue of $431.6 million.
How Is Novartis’s Cosentyx Positioned after 4Q17?
In 4Q17, Novartis’s (NVS) Cosentyx generated revenues of $615 million compared to $391 million in 4Q16, which reflected ~57% growth on a year-over-year (or YoY) basis and ~11% growth quarter-over-quarter.
Why Do Biotech Stocks Look Attractive?
Today, biotech is one of the hottest investment areas. It’s driven by the demand for effective treatments and new cures. Stocks had strong growth in recent years.
A Look at Ionis’s Revenue Streams in the Second Quarter
Ionis Pharmaceuticals (IONS) reported year-over-year (or YoY) growth of 5% in revenues to $118 million during Q2 2018 as compared to the revenues of $112 million during the second quarter of 2017.
AbbVie Has Raised Its EPS Guidance for 2018
On its second-quarter earnings conference call, AbbVie (ABBV) raised its 2018 EPS guidance by $0.10.
Celgene’s Revlimid Expected to Post Strong Revenue in 2017
According to unaudited financial results published by Celgene (CELG) on January 9, 2017, Revlimid sales for 2016 are about $7.0 billion, a YoY rise of about 20.0%.
What Does the Future Hold for Seattle Genetics?
Seattle Genetics has surpassed all estimates for earnings per share in the past.
What Analysts Recommend for Celgene in 2017
Celgene (CELG) has a focused and robust clinical pipeline that may help it launch new drugs in the future.
Here Are the Latest Analyst Recommendations for Biogen
The consensus 12-month target price for Biogen is $342.7, an ~11.4% return potential.
Alexion Pharmaceuticals Adds Metabolic Drug Kanuma to Portfolio
Kanuma was acquired by Alexion Pharmaceuticals on completion of the acquisition of Synageva Pharmaceuticals in June 2015.
XLV Was Trading Higher after Paying Dividends
The Health Care Select Sector ETF (XLV) rose by 1.1% and closed at $72.38 on December 23. XLV is trading well above its 20-day, 50-day, and 100-day moving averages.
Must-Read: Amgen’s 3Q15 Earnings and Conference Call
In its 3Q15 earnings report released on October 28, Amgen reported YoY revenue growth of ~14.0%, from $5.0 billion in 3Q14 to $5.7 billion in 3Q15.
Analyzing the Performance of Celgene’s Hematology Portfolio
Celgene’s total worldwide sales of the hematology/oncology category increased from $2.7 billion in 1Q17 to $3.1 billion in 1Q18.
What to Expect from BioMarin Pharmaceuticals in 2017
In 2016, BioMarin Pharmaceuticals (BMRN) reported revenues of around $1.1 billion, a ~25% increase year-over-year (or YoY).
Performance of Celgene’s Inflammation and Immunology Products
Total worldwide sales of Celgene’s other products—including Idhifa, Thalomid, and Istodax—increased from $226.0 million in 1Q17 to $229.0 million in 1Q18.
Inside Celgene’s Revlimid: Strong Patient Demand in 4Q16
After the approval of the drug as a therapy for newly diagnosed multiple myeloma, Celgene’s Revlimid has witnessed rapid growth in market share worldwide.
Analysts Expect Biogen’s Net Profit Margins to Rise in 3Q15
Biogen’s (BIIB) 3Q15 earnings results will be announced on October 21, 2015. Analysts expect that the company will report lower net profit margins as compared to 2Q15.
What Celgene Projects for Its Fiscal 2018 Revenue
Wall Street analysts expect Celgene to report revenues of $15.22 billion in fiscal 2018.
How Xtandi Fueled Big Pharmaceutical Interest in Medivation
Xtandi is the major factor behind Pfizer’s (PFE) interest in Medivation (MDVN). The drug, along with MDVN’s pipeline molecules, should strengthen Pfizer’s (PFE) oncology franchise.
Venclexta May Prove a Novel Chemotherapy-Free Treatment Option
In 2017, AbbVie (ABBV) and Roche Holdings’ (RHHBY) Venclexta reported positive data from its Phase 3 trial, MURANO.
Imbruvica Continues to Expand across Indications and Lines of Therapy
Imbruvica managed to earn revenues of about $381 million in 1Q16, which comprised of $325 million from the US market and $56 million from foreign markets.
Acceleron Pharmaceuticals and Celgene Rise on Meeting Study Goals
Today, Celgene (CELG) and Acceleron Therapeutics (XLRN) stocks are trending higher on the news of their Phase 3 clinical trial for luspatercept meeting its goal.
Third Point Partners ups stake in Amgen
The fund noted in its letter that “Amgen has all the hallmarks of a hidden value situation, which is one of the fund’s favorite investment themes.”
Amgen Stock Rises over 2% on Drug Approvals
Amgen (AMGN) stock has risen ~2.3% in the last week following recent drug approvals.
Celgene Stock Performance in 1Q18
Wall Street analysts estimate that Celgene (CELG) stock has the potential to return 31.6% over the next 12 months.
What Drove Ionis’s Revenue in Q1
In the first quarter, leading biopharmaceutical company Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million.
Inside Bristol’s Key to Success: Multiple Labels for Opdivo
Opdivo’s significant regulatory advances over the past quarter include approval for head and neck cancer indications, among others.
Allergan Boosts XLV Large-Caps with Positive 4Q15 Earnings
Allergan (AGN) reported its 4Q15 earnings on February 22, 2016. It reported net revenue of $4.2 billion for 4Q15, an increase of 74% compared to $2.4 billion in 4Q14.
BlueBird Bio Stock Jumps over 6% on May 17
BlueBird Bio stock has risen ~119.9% over the last 12 months and 6.3% year-to-date.
JNJ’s Stelara Witnessed High Growth in 3Q17
In 3Q17, Johnson & Johnson’s (JNJ) Stelara generated revenues of $1.1 billion, which reflected ~38% growth on a YoY basis and 14% growth on a quarter-over-quarter basis.
Eli Lilly’s Neuroscience Products Sales Dropped in Q2 2018
Zyprexa reported revenues of $128.0 million in Q2 2018, a 9.0% decline in YoY revenues compared to $140.8 million in Q2 2017.
How Celgene Reacted to Positive Clinical Trials on October 26, 2015
Celgene rose by 2.95% and closed at $123.65, surpassing its 50- and 100-day moving average prices of $118.45 and $121.09.
What Were the Top Holdings of Citadel Advisors in Q3?
In Q3 2019, Citadel Advisors’ portfolio of publicly traded securities was worth $212.04 billion. In Q2 2019, its portfolio was worth $155.1 billion.
New Indications May Be Big Opportunity for AbbVie’s Imbruvica
On September 26, 2016, AbbVie (ABBV) said it has submitted an application to the FDA for Imbruvica as a treatment for previously treated patients with marginal zone lymphoma.
Revlimid Could Continue to Drive Celgene’s Revenue Growth in 2017
In 2016, Celgene’s (CELG) Revlimid generated revenues of around $6.9 billion, which reflected a ~20% year-over-year (or YOY) growth.
Biogen Trades at High Valuation Multiples Due to Strong Research Pipeline
After the release of its 3Q15 earnings results on October 21, Biogen was trading at PE multiples in the range of 13.8x–15.3x.
Celgene to File NDA for Ozanimod as Multiple Sclerosis Therapy
If ozanimod captures a significant share in the evolving multiple sclerosis market, it may have a positive impact on Celgene stock.
Horizon Pharma Appears to Be on an Acquisition Spree
Horizon Pharma (HZNP), after acquiring Vidara Therapeutics on September 19, 2014, completed its second acquisition of Hyperion Therapeutics (HPTX) on May 7, 2015.
Overview: Highbridge Capital Management’s 2Q14 positions
Highbridge Capital Management is an alternative investment management organization. It was founded in 1992. The company has developed a diversified investment platform.
Pfizer’s Growth Rate and Estimates
Pfizer (PFE) reported an EPS of $0.74 on revenues of ~$13.5 billion during the second quarter, which beat analysts’ estimate of ~$13.3 billion.
Novartis Enters Agreement to Acquire AveXis
On April 9, 2018, Novartis AG announced that it had entered into an agreement to acquire AveXis for ~$8.7 billion.
Pharma’s Latest: Mergers and Acquisitions in 1Q18
Let’s take a look at the mergers and acquisitions that took place in the US pharmaceutical sector in 1Q18.
Behind Celgene’s Blockbuster Revenue Hit in 4Q16
In 2016, Celgene’s (CELG) Otezla attained blockbuster status by earning revenues in excess of $1 billion as a therapy for psoriasis and psoriatic arthritis.
Amgen Expects Competitive Pressures for Its Mature Brands in 2016
Following the launch of Novartis’s biosimilar Zarxio in September 2015, Amgen’s Neupogen, a short-acting filgrastim, has witnessed a gradual fall in its revenue.
The George Soros Fund Shares 13F Analysis
On November 14, The George Soros Fund Management LLC filed 13F. The firm’s total market value was around $3.6 billion at the end of Q3 2019.
What’s Gilead Sciences’ Valuation?
Gilead’s stock price has risen ~8.9% in the last 12 months. Wall Street analysts estimate that the stock price will fall ~4.5% over the next 12 months.
How Kanuma’s Addition to Alexion’s Portfolio Impacts Its Earnings
Alexion added Kanuma to its portfolio in 2015 after its Synageva acquisition. But ALXN didn’t have much time to build diagnostics as it did with Strensiq.
AstraZeneca’s Oncology Segment: How Did It Perform in 2Q15?
AstraZeneca’s oncology segment is another key focus area. The segment contributed 11.6% in 2014 and 12.1% in 2Q15. Key products for oncology are Zoladex and Faslodex.
Is Antitrust a Risk in the Pharmacyclics–AbbVie Merger?
In preparation for the Pharmacyclics–AbbVie merger, the companies will have to file under the Hart-Scott-Rodino Antitrust Improvements Act.
What’s in Celgene’s Immunology and Inflammation Clinical Pipeline?
Celgene has entered a strategic collaboration with Acceleron for the development of luspatercept.
Celgene’s Otezla Expected to Post Strong Revenue in 2017
According to unaudited financial results for Celgene (CELG) on January 9, 2017, Otezla sales for 2016 were about $1.0 billion. That’s a YoY rise of about 116.0%.
How Much Does Biogen Spend on Research and Development?
Biogen’s (BIIB) R&D expenses for 4Q15 were $542 million, or 19% of its total revenue, including a $60 million payment to Mitsubishi Tanabe.
Allergan’s 1Q18 Earnings: Analysts’ Estimates
Allergan (AGN) plans to release its 1Q18 earnings on April 30. Wall Street expect AGN’s earnings per share to reach $3.36.
Xeljanz ER Is Driving Growth for Pfizer This Year
On July 28, 2016, Pfizer announced positive results from the Phase 3 trial testing efficacy of Xeljanz as therapy for patients suffering with moderate to severely active ulcerative colitis (or UC).
BioMarin: How Much Revenue Growth in 2Q16?
According to analyst estimates, BioMarin should earn $278.4 million and $273.5 million in 2Q16 and 3Q16, respectively. That’s a yearly sales growth of 11.1% and 30.9%, respectively.
How’s Celgene’s Abraxane Positioned after 4Q17?
In 4Q17, Celgene’s (CELG) Abraxane generated revenues of $251 million, which reflected a decline of ~6% on a YoY (year-over-year) basis.
Why Sesen Bio Stock Jumped Over 37% this Week
Sesen Bio (SESN), formerly known as Eleven Biotherapeutics, is developing next-generation antibody-drug conjugate therapies. The stock jumped ~26.1% to $2.27 yesterday.
Gilead Sciences’ Valuation Continues to Lag behind Peers
Post 2014, Gilead Sciences has traded at lower valuation multiples, as investors are uncertain of the company’s ability to continue its leadership in the global HIV market.
What Do Analysts Recommend for AbbVie?
Analysts updated their recommendations for AbbVie (ABBV) after the release of its 1Q16 earnings on April 28, 2016.
Which Biotechnology Companies Could Benefit from Brexit?
The weak pound is expected to negatively affect biotechnology companies with a high revenue exposure to the United Kingdom.
What Biogen Is Doing that Put It in Good Favor with Analysts
Based on recommendations from 25 broker companies, a Bloomberg survey reported that 62.5% of analysts gave Biogen (BIIB) “buy” recommendations.
How Celgene’s Pomalyst Is Positioned after 2Q17
In 2Q17, Celgene’s (CELG) Pomalyst generated revenues of ~$391 million, which reflected ~23% growth on a year-over-year basis.
Gilead Sciences in 4Q15: Analysts Project Modest Revenue Growth
On February 02, 2016, Gilead Sciences will announce its 4Q15 earnings for the period ending December 31, 2015. Analysts expect modest revenue growth.
How Did AbbVie Perform in 1Q16?
AbbVie posted its 1Q16 earnings on April 28, 2016. The company registered diluted EPS (earnings per share) attributable to common shareholders of $1.15.
Celgene’s Operating Expenses in 3Q15
In 3Q15, Celgene’s gross profit margin improved due to a favorable product mix composed mainly of Revlimid, Pomalyst, and Otezla.
Inside AbbVie’s Analyst Recommendations in 2016
Based on 24 recommendations, Bloomberg reported that 59.1% of analysts gave AbbVie a “buy” recommendation, while 36.4% of analysts gave the stock a “hold.”
Celgene Estimates Robust Revenue in 2017
In 2017, Celgene (CELG) expects to earn revenues of $13.0 billion–$13.4 billion, which would be a YoY (year-over-year) growth of around 18.0%.
What Do Analysts Have to Say about Bristol-Myers Squibb?
Analyst recommendations for BMY Bristol-Myers Squibb (BMY) is a leading immuno-oncology company. According to a Bloomberg consensus of 26 brokerage firms recorded on October 5, 2016, 42.3% of analysts recommended Bristol as a “buy” and 50% of analysts issued a “hold” rating for the company. Around 7.7% of analysts rated the stock as a “sell.” The […]
Horizon Pharma’s Specialty Business Unit in 2Q15
As per a company press release, Horizon Pharma’s (HZNP) specialty business unit consists of two products: RAYOS and Lodotra.
An Easier Way to Understand the Pharma Industry
In 2018, the global pharmaceutical industry stood at $1.2 trillion, and experts expect $1.5 trillion by 2023. Here’s everything investors need to know.
Third Point believes Amgen’s acquisitions should have done more
Faced with expiring patents and increasing competition for its blockbuster drugs, Amgen acquired Onyx to benefit from the latter’s innovative oncology portfolio and pipeline.
Renaissance Technologies: Analyzing Its Q3 13F
At the end of the third quarter, Bristol-Myers Squibb, Celgene, Biogen, UnitedHealth, and Walmart (WMT) were Renaissance Technologies’ top five buys.
AbbVie Expects Peak Sales of $7 Billion for Imbruvica
AbbVie (ABBV) has projected Imbruvica’s annual revenues to be $5 billion by 2020. That would be driven by a rapid uptake in the first line chronic lymphocytic leukemia (or CLL) segment.
AbbVie’s Venclexta for Chronic Lymphocytic Leukemia
AbbVie (ABBV) and Roche Holdings (RHHBY) have strategized to position Venclexta as a foundation therapy in the chronic lymphocytic leukemia (or CLL) indication.
Analyzing Tudor Investment’s Top Holdings
Tudor Investment founder Paul Tudor Jones II’s macro investment strategies have helped investors understand the opportunities in various securities.
Renaissance Technologies: Top Investments
Renaissance Technologies had a strong investment in the healthcare sector in Q2 2019. The healthcare sector makes up 18.16% of the firm’s total portfolio.
Amgen and Celgene’s Otezla Deal: Key Highlights
On August 26, Amgen (AMGN) announced the purchase of leading immunology drug Otezla from Celgene (CELG) for a cash consideration of $13.4 billion.
How PFE’s and BMY’s EPS Trends Compare
In fiscal 2019, Pfizer (PFE) expects its adjusted diluted EPS to fall 4.0% YoY (year-over-year) to $2.83–$2.93.
Bristol-Myers Squibb’s Oncology Treatment Growth Drivers
Revenue for Bristol-Myers Squibb’s (BMY) Opdivo has grown by a double-digit percentage YoY (year-over-year) since 2016.
What Analysts Recommend for Bristol-Myers Squibb and Celgene
The consensus recommendation for Bristol-Myers Squibb is a “buy,” while the consensus for Celgene is a “hold.”
What’s the Latest on the BMY-Celgene Deal?
Starboard Value has decided to give up the proxy war to stop Bristol-Myers Squibb’s deal with Celgene.
Roche Holdings to Acquire Spark Therapeutics
On February 25, Roche Holdings (RHHBY) issued a press release announcing that it has entered a definitive agreement to acquire Spark Therapeutics (ONCE).
ABBV or CELG: Comparing Dividends, Interest Expenses, and Debt
AbbVie (ABBV) and Celgene (CELG) reported dividends per share of $3.59 and $0.0, respectively, in 2018.
AbbVie or Celgene: Which Is Expected to Report Faster EPS Growth?
On its fourth-quarter earnings conference call, AbbVie (ABBV) guided for an adjusted gross margin of 82.5% in 2019.
Is AbbVie or Celgene Expected to Report Faster Revenue Growth?
On January 3, Bristol-Myers Squibb (BMY) issued a press release announcing that it had entered into a definitive agreement to acquire Celgene.
What Analysts Recommend for AbbVie and Celgene This Month
On February 5, AbbVie (ABBV) closed at $79.69, 1.48% higher than its previous closing price, 5.17% higher than its 52-week low of $75.77.
Revlimid and Pomalyst Continued to Be Growth Drivers for Celgene
On January 7, 2019, Celgene (CELG) issued a press release announcing its strategy to maximize the commercial potential of its major revenue-earning hemato-oncology assets.
Can Celgene’s Revenues Impress the Market in Q4 2018?
On January 7, Celgene (CELG) issued a press release announcing that the company earned revenues of $15.2 billion for fiscal 2018.
Celgene and Bristol-Myers Squibb’s Deal: What Are the Benefits?
Bristol-Myers Squibb’s (BMY) acquisition of Celgene (CELG) will add the latter’s blockbuster multiple myeloma (or MM) drugs, Revlimid and Pomalyst, to the company’s portfolio.
Ray Dalio’s Advice Is to ‘Go Counter-Cyclical’
Ray Dalio thinks of the markets in the context of the economic machine, wherein cycles repeat themselves.
Key Growth Drivers for Bristol-Myers Squibb Going Forward
Bristol-Myers Squibb (BMY) will target four major therapeutic areas after completing the acquisition of Celgene (CELG).
BMY and Celgene to Form a Leading Global BioPharma Company
According to Bristol-Myers Squibb’s (BMY) investor presentation, the company expects to create a leading oncology franchise across both solid tumor and hematologic malignancy segments.
Bristol-Myers Squibbs and Celgene: Cost Synergies for Future Years
According to Bristol-Myers Squibb’s (BMY) press release, the company expects the acquisition of Celgene (CELG) to result in annual cost synergies close to $2.5 billion.
What to Expect from Bristol-Myers Squibb’s Earnings in 2019
Bristol-Myers Squibb (BMY) expects to report GAAP EPS in the range of $3.05 to $3.15 and non-GAAP EPS in the range of $3.80 to $3.90 for fiscal 2018.
How Bristol-Myers Squibb’s Revenues Look Heading into 2019
In its third-quarter earnings conference call, Bristol-Myers Squibb (BMY) has forecasted high-single-digit YoY revenue growth for fiscal 2018.
What to Expect from BMY’s Celgene Acquisition
The acquisition of Celgene (CELG) by Bristol-Myers Squibb (BMY) brings together both the company’s leading franchises.
Bristol-Myers Squibb to Acquire Celgene
Bristol-Myers Squibb has agreed to acquire Celgene in a cash and stock transaction valued at around $74.0 billion.
Let’s Talk about Bristol-Myers Squibb’s 2019 EPS Guidance
Today, Bristol-Myers Squibb (BMY) is trading at $45.85, ~11.86% lower than its previous day’s closing price.
Taking Stock of bluebird bio’s Performance
In the third quarter, bluebird bio’s total revenue rose YoY (year-over-year) to $11.53 million from $7.71 million.
A Look at Abraxane’s Revenue Growth Trajectory in 2018
In its third-quarter earnings conference call, Celgene (CELG) reiterated its expectation for Abraxane’s fiscal 2018 net product sales of around $1.0 billion.